A life sciences company has sold off part of its business that includes a Morrisville facility with hundreds of workers.

Wave Life Sciences (WVE) shares rallied 74.1% in the last trading session to close at $14.90. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Joseph Schwartz, an analyst from Leerink Partners, reiterated the Buy rating on Wave Life Sciences (WVE – Research Report). The ...

Wave Life Sciences Ltd. said it achieved so-called proof-of-mechanism in a single-dose trial of its potential treatment for a genetic disorder that causes lung and liver diseases. Its stock surged as ...

While RNA-medicine developer Wave Life Sciences Ltd. brought in a clinical data win, it also got knocked back a step as a major collaborator will go its separate way. That didn’t stop Wave’s stock ...

Wave Life Sciences' alpha-1 antitrypsin deficiency candidate WVE-006 succeeded in the first-ever clinical demonstration of ...

Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE ...

Wave Life Sciences is a clinical-stage biotechnology company based in Cambridge, MA, dedicated to unlocking the potential of RNA medicines to transform human health. With a robust pipeline focused on ...

Wave Life Sciences (WVE) shares soared 66% after the company announced positive proof-of-mechanism data from a study of ...

Wave Life Sciences shares soared more than 70% on Wednesday after the biotech firm said it had successfully edited the RNA of ...

In terms of liquidity and interest, the mean open interest for WAVE Life Sciences options trades today is 608.71 with a total ...

The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.